| __timestamp | Agios Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 1860000 |
| Thursday, January 1, 2015 | 35992000 | 2963000 |
| Friday, January 1, 2016 | 50714000 | 6961000 |
| Sunday, January 1, 2017 | 71124000 | 11779000 |
| Monday, January 1, 2018 | 114145000 | 13697000 |
| Tuesday, January 1, 2019 | 132034000 | 15749000 |
| Wednesday, January 1, 2020 | 149070000 | 18638000 |
| Friday, January 1, 2021 | 121445000 | 27196000 |
| Saturday, January 1, 2022 | 121673000 | 31739000 |
| Sunday, January 1, 2023 | 119903000 | 33491000 |
| Monday, January 1, 2024 | 156784000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. From 2014 to 2023, Agios Pharmaceuticals consistently reported higher SG&A costs compared to Protagonist Therapeutics. Agios's expenses peaked in 2020, reaching nearly 150% more than their 2014 levels, while Protagonist's costs increased by approximately 170% over the same period. Despite Agios's larger scale, Protagonist's more modest growth in expenses suggests a tighter control over SG&A costs. This trend highlights Protagonist's strategic focus on cost efficiency, potentially offering a competitive edge in the biotech sector. As the industry evolves, these financial strategies could play a pivotal role in determining long-term success.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.